The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes

被引：18
作者：
Steen, Oren [1 ]
Goldenberg, Ronald M. [2 ]
机构：
[1] LMC Diabet & Endocrinol, 1929 Bayview Ave,Suite 107, Toronto, ON M4G 3E8, Canada
[2] LMC Diabet & Endocrinol, Thornhill, ON, Canada
来源：
CANADIAN JOURNAL OF DIABETES | 2017年 / 41卷 / 05期
关键词：
type; 2; diabetes; sodium-glucose cotransporter 2 inhibitors; cardiovascular safety; canagliflozin; dapagliflozin; empagliflozin; INADEQUATE GLYCEMIC CONTROL; DOUBLE-BLIND; SGLT2; INHIBITORS; BLOOD-PRESSURE; ADD-ON; KIDNEY-DISEASE; EMPAGLIFLOZIN; DAPAGLIFLOZIN; SAFETY; EFFICACY;
D O I：
10.1016/j.jcjd.2017.08.241
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Sodium-glucose cotransporter 2 (SGTL2) inhibitors are a novel class of antihyperglycemic agents that work in an insulin-independent manner by promoting urinary glucose excretion. In addition to efficacious glucose lowering, they exert beneficial effects on blood pressure and weight while avoiding hypoglycemia unless combined with insulin or insulin secretagogues. This review explores the mechanism of action of SGLT2 inhibitors, their effects on glycated hemoglobin, weight, blood pressure and hypoglycemia, potential adverse effects, renal considerations and cardiovascular outcomes. (C) 2017 Canadian Diabetes Association.
引用
收藏
页码：517 / 523
页数：7
相关论文
共 73 条
  • [1] [Anonymous], 2016, INV CAN TABL 100 MG
  • [2] [Anonymous], 2016, FORX DAP TABL DAP PR
  • [3] [Anonymous], 2013, CAN J DIABETES S3, V37, pS357
  • [4] [Anonymous], 2015, SUMM SAF REV SOD GLU
  • [5] [Anonymous], 2010, JARD EMP TABL 10 MG
  • [6] AstraZeneca, 2012, MULT TRIAL EV EFF DA
  • [7] Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
    Barnett, Anthony H.
    Mithal, Ambrish
    Manassie, Jenny
    Jones, Russell
    Rattunde, Henning
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (05) : 369 - 384
  • [8] Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials
    Berhan, Asres
    Barker, Alex
    [J]. BMC ENDOCRINE DISORDERS, 2013, 13
  • [9] Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
    Bilezikian, John P.
    Watts, Nelson B.
    Usiskin, Keith
    Polidori, David
    Fung, Albert
    Sullivan, Daniel
    Rosenthal, Norm
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (01) : 43 - 50
  • [10] Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
    Bolinder, Jan
    Ljunggren, Osten
    Kullberg, Joel
    Johansson, Lars
    Wilding, John
    Langkilde, Anna Maria
    Sugg, Jennifer
    Parikh, Shamik
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (03) : 1020 - 1031
12345678